Health · Pharma & Biotech · 5 hrs ago

FDA approves Regeneron’s RNAi drug for myasthenia gravis

FDA approves Regeneron’s RNAi drug for myasthenia gravis

The FDA approved Regeneron’s Livsayis on Nov.

18 for adults with a common form of generalized myasthenia gravis.

The autoimmune disease can cause debilitating muscle weakness.

Livsayis uses RNA interference to reduce production of C5, a protein involved in the immune response behind the condition.

The drug was discovered by Alnylam and licensed to Regeneron in 2019; it is the company’s first marketed RNAi medicine.

It is also the first RNAi drug approved for an autoimmune condition, showing how this type of treatment may be used beyond its earlier applications.

Livsayis is injected under the skin four times a year and will compete with established treatments from Argenx and AstraZeneca.

Its launch may be gradual as doctors weigh its use and side effects, though its less frequent dosing could help it gain patients over time.

2 sources

Related

What people are saying

Brian AbrahamsRBC Capital Markets analyst
Adoption is likely to be “measured at first,
via BioPharma Dive
Tyler Van BurenTD Cowen analyst
The market is expanding
via BioPharma Dive